Enzymit Secures $10M Series A to Revolutionize Cell-Free Bioproduction

Enzymit, an innovative synthetic biology company, has successfully closed a $10 million Series A funding round, with Grove Ventures and Khosla Ventures leading the investment. The round also saw continued support from existing investors First Star Ventures and Sapir Venture Partners. Furthermore, this fresh capital injection will accelerate the development of Enzymit’s cell-free bio-production technology, paving the way for faster, more cost-effective, and scalable enzyme-based manufacturing.

Transforming Enzyme Engineering with AI-Powered Design

Based in Israel, Enzymit is at the forefront of cell-free bioproduction, a breakthrough approach that eliminates the need for living cells in the manufacturing process. By leveraging advanced computational design, deep learning algorithms, and AI-driven enzyme engineering, the company is pioneering a new era of custom enzyme creation.

“For decades, bio-production has been constrained by the search for natural enzymes that happen to meet industrial needs,” said Dr. Gideon Lapidoth, CEO and co-founder of Enzymit. “Our AI-powered platform is changing this paradigm by designing entirely new enzymes tailored for specific production challenges. This allows us to create molecules and materials that were previously unattainable or prohibitively expensive to produce.”

The Future of Sustainable, Scalable Cell-Free Bioproduction

Enzymit’s synthetic biology platform holds significant promise across multiple industries, including pharmaceuticals, food technology, sustainable materials, and specialty chemicals. What is more, by eliminating biological constraints and optimizing enzyme function, the company’s technology enables high efficiency biomanufacturing with reduced costs, minimal waste, and greater precision.

With this new funding, Enzymit aims to expand its R&D efforts, enhance its AI-driven enzyme design capabilities, and accelerate commercial partnerships to bring its innovations to market. Moreover, as biotechnology and artificial intelligence continue to merge, Enzymit is positioning itself as a key player in the next generation of bio-industrial transformation.

>> Click here to read the full article originally published in CTech: 

https://www.calcalistech.com/ctechnews/article/b1k3mjxrr